期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

具有免疫效能的重建流行性感冒病毒体佐剂的研究进展 被引量：2

Summary of Studies of the IRIVs Adjuvant
原文传递
导出
摘要 具有免疫效能的重建流行性感冒(流感)病毒体(Immunopotentiating Reconstituted Influenza Virosomes,IRIVs)组分单纯,安全性好,是一种在疫苗发展中有着广泛应用前景的新型佐剂。作用机制类似于天然流感病毒,可同时有效诱导体液和细胞免疫,应用于甲型肝炎疫苗、流感疫苗、呼吸道合胞病毒疫苗、丙型肝炎疫苗、抗癌疫苗、联合疫苗等多种疫苗的开发与研制。以IRIVs为佐剂的疫苗,有已投入市场应用的爱巴苏和因福舒,还有多种病毒及寄生虫疫苗在临床评估及研究中。 New adjuvant IRIVs （Immunopotentiating Reconstituted Influenza Virosomes）have pure components and an excellent tolerability. The mechanism of action of IRIVs closely resembles that of the natural influenza virus,and can elicit a strong humoral and cellular immune response. IRIVs have application in the development of HAV vaccine, Flu vaccine, RSV vaccine, HCV vaccine,Anti-carcinoma vaccine and other vaccines. Two IRIVs vaccines are currently on the market： Epaxal and Inflexal,and a variety of new viral and parasitic vaccines are undergoing clinical evaluation and development. IRIVs have an extensive potential for the development of vaccines.
作者 张丽文 张勇
机构地区 北京市昌平区疾病预防控制中心 中国疾病预防控制中心病毒病预防控制所
出处 《中国计划免疫》 2007年第6期605-608,共4页 Chinese Journal of Vaccines and Immunization
关键词 具有免疫效能的重建流行性感冒病毒体 甲型肝炎疫苗 Immunopotentiating reconstituted influenza virosomes Hepatitis A vaccine
分类号 R186 [医药卫生—流行病学]
  • 相关文献

参考文献39

  • 1Gupta RK,Relyveld EH,Lindblad EB,et al.Adjuvants-a balance between toxicity and adjuvanticity[J].Vaccine,1993,11(3):293-306.
  • 2Gluck R,Metcalfe IC.New technology platforms in the development of vaccines for the future[J].Vaccine,2002,20 (Suppl 5):B10-16.
  • 3Gluck R,Metcalfe IC.Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems[J].Vaccine,2003,21 (7-8):611-615.
  • 4Gluck R,Mischler R,Brantschen S,et al.Immunopotentiating reconstituted in fluenza virus virosome vaccine delivery system for immunization against hepatitis A[J].J Clin Invest,1992,90 (6):2491-2495.
  • 5Seganti L,Superti F,Orsini N,et al.Membrane lipid components interacting with hepatitis A virus[J].Microbiologica,1989,12(3):225-230.
  • 6Zurbriggen R,Novak-Hofer I,Seelig A,et al.IRIV-adjuvanted hepatitis A vaccine:in vivo absorption and biophysical characterization[J].Prog Lipid Res,2000,39(1):3-18.
  • 7Zurbriggen R,Gluck R.Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice[J].Vaccine,1999,17(11-12):1301-1305.
  • 8Garcon NM,Six HR.Universal vaccine carrier:liposomes that provide T-dependent help to weak antigen[J].J Immunol,1991,146(11):3697-3702.
  • 9Durrer P,Galli C,Hoenke S,et al.H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 aminoterminal fusion peptide but not the coiled coil region[J].J Biol Chem,1996,271 (23):13417-13421.
  • 10Tsurudome M,Gluck R,Graf R,et al.Lipid interactions of the hemagglutinin HA2 NH2-terminal segment during influenza virus-induced membrance fusion[J].J Biol Chem,1992,267(28):20225-20232.

同被引文献21

  • 1常海艳,陈建军,方芳,陈则.流感病毒灭活疫苗新型佐剂——壳聚糖增强免疫作用研究[J].中国生物制品学杂志,2004,17(6):383-384. 被引量：12
  • 2王斌,徐苗.ISCOMATRIX^(TM)佐剂:细胞和体液免疫应答的有效诱导剂[J].国外医学（预防．诊断．治疗用生物制品分册）,2005,28(5):204-207. 被引量：5
  • 3王海漩,李卫东,廖国阳.流感疫苗佐剂的研究进展[J].中国生物制品学杂志,2007,20(3):224-226. 被引量：5
  • 4萨姆布鲁克J,拉塞尔D W,黄培堂,王嘉玺,朱厚础,等译.分子克隆实验指南[M]3版.北京:科学出版社,2002..
  • 5Scholtissek C ,Steeh j,Krauss S ,et al . Cooperation between the hemagglutinin of avian viruses and the matrix protein of human influenza A viruses[J]. J Virol,2002,76(4) : 1781-1786.
  • 6Aucouturier J,Dupuis L,Ganne V. Adjuvants designed for veterinary and human vaccines[J]. Vaccine, 2001,19 (6) : 2666-2672.
  • 7Zoltan Vajo, Lajos Kosa,Ildiko Visontay,et al. Inactivated Whole Virus Influenza A (H5N1)Vaccine[J]. Emerging Infectious Diseases, 2007,13(5) : 807-808.
  • 8Dumortier j, Schonig K, Oherwinkler H, et al. Liver- specific expression of interferon gamma following adenoviral gene transfer controis hepatitis B virus replication in mice[J]. Gene Ther, 9.005,12 (8) :668-677.
  • 9lain S. Karl G N. Anthony C. Boosting immunity to influenza H5N 1 with MF59-adjuvanted H5N3 A/Duck/SINGAPORE/97 vaccine in a primed human population [J].Vaccine, 2003, 21 ( 15 ), 1687- 1693.
  • 10Iorio AM,Francisci D,Camilloni B,et al. Antibody responses and HIV- 1 viral load in HIV- 1- seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non- adjuvanted subunit vaccine during highly active antiretroviral therapy[J]. Vaccine,2003,21(25-26):3629-3637.

引证文献2

中国计划免疫
2007年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部